Edgewise Therapeutics Inc (EWTX)


Stock Price Forecast

March 25, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Edgewise Therapeutics Inc chart...

About the Company

edgewise therapeutics is a biotechnology company focused on developing novel therapies for diseases involving skeletal muscle. the company is headquartered in boulder, co and received its series a financing from orbimed.

Exchange

NASDAQ

Website

edgewisetx.com

$M

Total Revenue

79

Employees

$1B

Market Capitalization

-10.81

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $EWTX News

Edgewise Therapeutics Inc EWTX

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

1mon ago, source: Nasdaq

--(BUSINESS WIRE)-- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year of 2023 ...

Wall Street Analysts See a 33.27% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?

1mon ago, source: Zacks.com on MSN

S hares of Edgewise Therapeutics, Inc. (EWTX) have gained 114.2% over the past four weeks to close the last trading session at $19.81, but there could still be a solid upside left in the stock if ...

Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know

1mon ago, source: Nasdaq

Shares of Edgewise Therapeutics, Inc. (EWTX) have gained 4.6% over the past four weeks to close the last trading session at $17.28, but there could still be a solid upside left in the stock if ...

Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference

22d ago, source: Stockhouse

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on EDG-5506, an investigational therapy designed to ...

Buy Rating Affirmed for Edgewise Therapeutics Amid Anticipated Positive Trial Outcomes and Strategic FDA Alignment

1mon ago, source: Business Insider

Edgewise Therapeutics (EWTX) Company Description: Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of ...

Edgewise Therapeutics Inc (NASDAQ: EWTX) -8.22% Decline Turns Away Investor Interest In Company’s Stock

10d ago, source:

Edgewise Therapeutics Inc (NASDAQ:EWTX) traded at $15.53 at close of the session on Monday, March 18, made a downward move of -8.22% on its previous day’s price.

Edgewise Therapeutics Inc.

29d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

1mon ago, source: Stockhouse

pro-forma cash balance exceeds $550M – Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full ...

Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference

20d ago, source: ADVFN

Company to host an Industry Forum to discuss its approach to protecting and preserving dystrophic muscle featuring key opinion leaders – Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading ...

EWTX Edgewise Therapeutics, Inc.

6d ago, source: Seeking Alpha

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...